Deepthi Ramesh

Dr. Deepthi Ramesh

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in European Journal of Pharmacology
Verified
Journal Article
Closed access
BGBalaji Vijayakumar Gowrivel
Balaji Vijayakumar Gowrivel
DRDeepthi Ramesh
Deepthi Ramesh
AJAnnu Joji
Annu Joji
JPJayadharini Jayachandra Prakasan
Jayadharini Jayachandra Prakasan
TKTharanikkarasu Kannan
Tharanikkarasu Kannan

1 December 2020 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
DRDeepthi Ramesh
Deepthi Ramesh
BGBalaji Vijayakumar Gowrivel
Balaji Vijayakumar Gowrivel
TKTharanikkarasu Kannan
Tharanikkarasu Kannan

1 July 2020 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
DRDeepthi Ramesh
Deepthi Ramesh
AJAnnu Joji
Annu Joji
BGBalaji Vijayakumar Gowrivel
Balaji Vijayakumar Gowrivel
ASAiswarya Sethumadhavan
Aiswarya Sethumadhavan
MMMaheswaran Mani
Maheswaran Mani
TKTharanikkarasu Kannan
Tharanikkarasu Kannan

15 March 2022 in RSC Advances
Verified
Journal Article
Open access
PDF file
LMLakshmi Haritha Bharathi Maganti
Lakshmi Haritha Bharathi Maganti
DRDeepthi Ramesh
Deepthi Ramesh
BGBalaji Vijayakumar Gowrivel
Balaji Vijayakumar Gowrivel
MKMohd Imran K. Khan
Mohd Imran K. Khan
ADArunkumar Dhayalan
Arunkumar Dhayalan
TKTharanikkarasu Kannan
Tharanikkarasu Kannan
In an attempt to find novel anti-mycobacterial agents, novel acetylene containing 2-(2-hydrazinyl)thiazole derivatives have been synthesized and evaluated against Mycobacterium tuberculosis .

7 June 2022 in RSC Advances
Verified
Journal Article
Open access
PDF file
DRDeepthi Ramesh
Deepthi Ramesh
AMAmaresh Kumar Mohanty
Amaresh Kumar Mohanty
ADAnirban De
Anirban De
BGBalaji Vijayakumar Gowrivel
Balaji Vijayakumar Gowrivel
ASAiswarya Sethumadhavan
Aiswarya Sethumadhavan
TKTharanikkarasu Kannan
Tharanikkarasu Kannan
A series of novel uracil derivatives such as bispyrimidine dione and tetrapyrimidine dione derivatives were designed based on the existing four-point pharmacophore model as effective HIV capsid protein inhibitors. The compounds were initially docked with an HIV capsid protein monomer to rationalize the ideas of design and to find the potential binding modes. The successful design and computational studies led to the synthesis of bispyrimidine dione and tetrapyrimidine dione derivatives from uracil and aromatic aldehydes in the presence of HCl using novel methodology. The in vitro evaluation in HIV p24 assay revealed five potential uracil derivatives with IC50 values ranging from 191.5 μg ml−1 to 62.5 μg ml−1. The meta-chloro substituted uracil compound 9a showed promising activity with an IC50 value of 62.5 μg ml−1 which is well correlated with the computational studies. As expected, all the active compounds were noncytotoxic in BA/F3 and Mo7e cell lines highlighting the thoughtful design. The structure activity relationship indicates the position priority and lower log P values as the possible cause of inhibitory potential of the uracil compounds.

26 April 2022 in Journal of Materials Chemistry B
Verified
Journal Article
Closed access
PDF file
BGBalaji Vijayakumar Gowrivel
Balaji Vijayakumar Gowrivel
DRDeepthi Ramesh
Deepthi Ramesh
KMK. Santhosh Manikandan
K. Santhosh Manikandan
MTMary Theresa
Mary Theresa
ASAiswarya Sethumadhavan
Aiswarya Sethumadhavan
TKTharanikkarasu Kannan
Tharanikkarasu Kannan
Conventional antimicrobial agents are losing the war against drug resistance day-by-day. Chitosan biopolymer is one of the alternative materials that lends itself well to this application by fine-tuning its bioactivity using different pendant groups. Herein, we report the synthesis of novel chitosan with pendant (E)-5-((4-acetylphenyl)diazenyl)-6-aminouracil (APAU) groups by forming Schiff base linkages between chitosan and the pendant groups. These chitosan biopolymers with pendant APAU groups form films superior in thermal stability compared to the neat chitosan. Interestingly, APAU alone was inactive against K. pneumoniae, E. coli, S. aureus, T. rubrum and C. albicans. However, novel chitosan samples were active against S. aureus with an MIC of 390 μg mL−1, half that of plain chitosan at 780 μg mL−1. APAU modified chitosan samples, CA80 and CA100 showed an MIC (against K. pneumoniae and E. coli) of 23.4 μg mL−1, superior to plain chitosan's MIC of 187.5 μg mL−1 and is close to commercial Fluconazole's MIC of 11.7 μg mL−1. The activity of chitosan changes with APAU content and at higher concentrations shows a strong synergetic antimicrobial effect.